logo
Twitter
Discord
Email
logo
SIGA Technologies, Inc.

SIGA Technologies, Inc.

NASDAQ•SIGA
CEO: Dr. Dennis E. Hruby Ph.D.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Listing Date: 1997-09-10
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.
Contact Information
31 East 62nd Street, New York, NY, 10065, United States
212-672-9100
www.siga.com
Market Cap
$607.22M
P/E (TTM)
7.4
vs Industry 35.1
Dividend Yield (TTM)
7.1%
52W High
$9.62
52W Low
$4.95
52W Range
76%
5.1
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q2 2025 Data

Revenue

$81.12M+271.92%
4-Quarter Trend

EPS

$0.50+1824.42%
4-Quarter Trend

FCF

$63.08M+960.03%
4-Quarter Trend

Earnings Highlights

Key Highlights

No Data Available

Risk Factors

No Data Available

Outlook

No Data Available

Peer Comparison

Revenue (TTM)

Emergent BioSolutions Inc.EBS
$846.20M
-23.2%
Orthofix Medical Inc.OFIX
$809.03M
+4.8%
SNDL Inc.SNDL
$676.71M
+3.5%

Gross Margin (Latest Quarter)

CytomX Therapeutics, Inc.CTMX
100.0%
+0.0 pp
Esperion Therapeutics, Inc.ESPR
75.0%
-3.9 pp
Orthofix Medical Inc.OFIX
68.7%
+3.0 pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
DRIO$745.24M-20.4-57.6%29.2%
AQST$692.12M-10.6108.8%134.7%
RGNX$673.42M-3.9-67.0%46.8%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4-Quarter Revenue CAGR
+100.9%
Strong Growth
4-Quarter Net Income CAGR
+197.8%
Significant Improvement in Profitability
Cash Flow Stability
75%
Volatile Cash Flow

Research & Insights

Reports
All Years

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 5, 2025|
    Revenue: $81.12M+271.9%
    |
    EPS: $0.50+1824.4%
    N/A

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 8, 2025|
    Revenue: $7.04M-72.3%
    |
    EPS: $-0.01-107.1%
    N/A

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 11, 2025|
    Revenue: $138.72M-0.9%
    |
    EPS: $0.83-12.6%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 7, 2024|
    Revenue: $10.01M+8.4%
    |
    EPS: $0.02-441.8%
    Miss

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 1, 2024|
    Revenue: $21.81M+271.0%
    |
    EPS: $0.03-163.9%
    Miss

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 7, 2024|
    Revenue: $25.43M+205.5%
    |
    EPS: $0.14-1202.4%
    N/A

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 12, 2024|
    Revenue: $139.92M+26.3%
    |
    EPS: $0.95+106.5%
    Miss

  • Form 10-Q - Q3 2023

    Period End: Sep 30, 2023|Filed: Nov 7, 2023|
    Revenue: $9.24M-87.2%
    |
    EPS: $-0.01-101.2%
    N/A